SCHEMBL5574074

SCHEMBL5574074

CC(C)(C)OC(=O)N1CCC(CC(N)CC2CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.50
KDM4E B2RXH2 2/20 0.49
DPP4 P27487 1/20 0.49
PKM P14618 1/20 0.49
RECQL P46063 1/20 0.48
EPHX1 P07099 1/20 0.48
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR119 Q8TDV5 4/20 0.45
FAAH O00519 1/20 0.44
NR1H2 P55055 1/20 0.44
MAPT P10636 2/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
THRB P10828 1/20 0.44
PTPN2 P17706 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28643401 0.93 DPP4 (0.49) HPGDKDM4EDPP4PKMRECQL
SCHEMBL28647908 0.93 DPP4 (0.49) HPGDKDM4EDPP4PKMRECQL
SCHEMBL20504518 0.91 RECQL (0.47) HPGDKDM4EDPP4PKMRECQL
SCHEMBL20601282 0.90 HPGD (0.45) HPGDKDM4EDPP4PKMRECQL
SCHEMBL6129221 0.89 HPGD (0.49) HPGDKDM4EDPP4PKMRECQL
SCHEMBL20618515 0.89 HPGD (0.49) HPGDKDM4EDPP4PKMRECQL
SCHEMBL12061214 0.89 HPGD (0.49) HPGDKDM4EDPP4PKMRECQL
SCHEMBL14260254 0.89 DPP4 (0.44) HPGDKDM4EDPP4PKMRECQL
Hydrochloric Acid SCHEMBL28354870 0.88 HPGD (0.48) HPGDKDM4EDPP4PKMRECQL
SCHEMBL23850578 0.87 HPGD (0.47) HPGDKDM4EDPP4PKMRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 HPGD 1987/4885KDM4E 218/4885DPP4 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.